Delivered-To: sometime5858@gmail.com
Received: by 2002:a9d:6153:0:0:0:0:0 with SMTP id c19-v6csp30252otk;
        Fri, 31 Aug 2018 17:02:35 -0700 (PDT)
X-Google-Smtp-Source: ANB0VdbvbWpIas/j0tM9e96MpNaeg3k7W+qs7kHnylRV98rlHQx6r0zZzmaVa1Is/8q+e7iiOlxl
X-Received: by 2002:adf:dfca:: with SMTP id q10-v6mr11701641wrn.113.1535760154947;
        Fri, 31 Aug 2018 17:02:34 -0700 (PDT)
ARC-Seal: i=1; a=rsa-sha256; t=1535760154; cv=none;
        d=google.com; s=arc-20160816;
        b=rukJZ0sbehtlDsOXg3gmpi2OwSfrq/goTpbYGJ9uJZaa+47QsUD9WBLbI5s9AFQt1F
         TmvfXzfOJmfBmpMvhDwpo9pFUZk1TB1/pobO5xJ6pmSVcJft9FAZ9AR8+RjICfF3Ubs+
         aMyzGEOnl8QoWjZs5oBcetZMS0AB7DWi632aOVKWMDa1S/95nBvWT3i7qhgmDEsn3BI8
         zJyn0q4L0v0mQicbcRaENQ0fPVFb1wPP0IWvkZLKGgzLvHIGNlDaMAiTM9A5KLG2OKIJ
         dt1gvhAqoAyO3Fg9XYIXH4UH5OVgo0440pSX3MAM2s3/tAFnpl0UQDeWCY6wZ7WbC5H9
         pRXQ==
ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20160816;
        h=mime-version:spamdiagnosticmetadata:spamdiagnosticoutput
         :content-language:accept-language:in-reply-to:references:message-id
         :deferred-delivery:date:thread-index:thread-topic:subject:from
         :dkim-signature:arc-authentication-results;
        bh=F3T1XDP4WXeLENSn9XN5I3zRsjS06piNRsObeu4bR/E=;
        b=RM1TtFe6NAht3b11Fkvs6e9/tj/PTL+489kpeqpLUS+fyqkB+I5gHQT6pndelVaayl
         a3dwNAHllDMZYBpnYZN7nwdWrahtKACS24LyAoyNrRbJOz/m1N46Axvv6nv266vt3E1E
         hy2l/4EtXOlyOivVju8g+8LA40eeb0wYMweliFVEUgYcZUeJXpq8k1KJkQB8EITAIYgb
         14LRkKRCtuZVeQL2H8KOKF81iKF8BXU5TGwuqNV9GrIVR7bf0eK+xjBCeqNwZHUFJ1pE
         nvQ9500RoRcrq/obORA7xvEiVXNzqBrrMGi1ODj2jFA+XfCswfv3Q+kKf8VOKHZYvtWL
         8THA==
ARC-Authentication-Results: i=1; mx.google.com;
       dkim=pass header.i=@NucleusNetwork.onmicrosoft.com header.s=selector1-nucleusnetwork-com-au header.b=Y6A29tbP;
       spf=pass (google.com: domain of reply@nucleusnetwork.com.au designates 104.47.117.127 as permitted sender) smtp.mailfrom=reply@nucleusnetwork.com.au
Return-Path: <reply@nucleusnetwork.com.au>
Received: from AUS01-SY3-obe.outbound.protection.outlook.com (mail-sy3aus01on0127.outbound.protection.outlook.com. [104.47.117.127])
        by mx.google.com with ESMTPS id s62-v6si4058623wmb.179.2018.08.31.17.02.26
        (version=TLS1_2 cipher=ECDHE-RSA-AES128-SHA bits=128/128);
        Fri, 31 Aug 2018 17:02:34 -0700 (PDT)
Received-SPF: pass (google.com: domain of reply@nucleusnetwork.com.au designates 104.47.117.127 as permitted sender) client-ip=104.47.117.127;
Authentication-Results: mx.google.com;
       dkim=pass header.i=@NucleusNetwork.onmicrosoft.com header.s=selector1-nucleusnetwork-com-au header.b=Y6A29tbP;
       spf=pass (google.com: domain of reply@nucleusnetwork.com.au designates 104.47.117.127 as permitted sender) smtp.mailfrom=reply@nucleusnetwork.com.au
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed;
 d=NucleusNetwork.onmicrosoft.com; s=selector1-nucleusnetwork-com-au;
 h=From:Date:Subject:Message-ID:Content-Type:MIME-Version:X-MS-Exchange-SenderADCheck;
 bh=F3T1XDP4WXeLENSn9XN5I3zRsjS06piNRsObeu4bR/E=;
 b=Y6A29tbPBlzam4ZqUA1fTg4dd6k3mhSTGxSlXtHGFAptFH+p50iKQWheqtNgbJOcW4xxY7MbN7rq90aRptD3HZsJ3y/j8qZ2wQ/AqT3aN4Aa/KRednQcB2jg2QPHpbBlzx3RaJl85wuDSYrhIFny7e9IfFaaNQandbn+BCGsmJo=
Received: from SYXPR01MB0463.ausprd01.prod.outlook.com (10.162.73.19) by
 SYXPR01MB1566.ausprd01.prod.outlook.com (10.171.39.19) with Microsoft SMTP
 Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id
 15.20.1080.17; Sat, 1 Sep 2018 00:02:08 +0000
Received: from SYXPR01MB0463.ausprd01.prod.outlook.com
 ([fe80::d8a5:4516:4fd9:10c]) by SYXPR01MB0463.ausprd01.prod.outlook.com
 ([fe80::d8a5:4516:4fd9:10c%6]) with mapi id 15.20.1101.016; Sat, 1 Sep 2018
 00:02:08 +0000
From: Centre for Clinical Studies <reply@nucleusnetwork.com.au>
Subject: Weekly Update- A list of all our studies
Thread-Topic: Weekly Update- A list of all our studies
Thread-Index:
 AdQ1/2KXHfoskjPxQWizusuEuV/zGAFd9ISwAAHG+hAAAMbm0AFdZDjAAACs6YAAAAru0A==
Date: Sat, 1 Sep 2018 00:01:17 +0000
Deferred-Delivery: Sat, 1 Sep 2018 00:00:00 +0000
Message-ID:
 <SYXPR01MB0463964C2DD1263171DC8222C50E0@SYXPR01MB0463.ausprd01.prod.outlook.com>
References:
 <SY3PR01MB0457274F2975663FD11A3E2DC53D0@SY3PR01MB0457.ausprd01.prod.outlook.com>
 <SYXPR01MB0463E403DAF58B6C914A6047C5360@SYXPR01MB0463.ausprd01.prod.outlook.com>
 <SYXPR01MB046368E47599ABC0E2DE3CD1C5360@SYXPR01MB0463.ausprd01.prod.outlook.com>
 <SYXPR01MB0463FA5A3BED8BA1DF7CDD80C5350@SYXPR01MB0463.ausprd01.prod.outlook.com>
 <SYXPR01MB0463D5FD8804DB64836B7BD1C50F0@SYXPR01MB0463.ausprd01.prod.outlook.com>
 <SYXPR01MB0463ECF852AA9D4DB30D0841C50F0@SYXPR01MB0463.ausprd01.prod.outlook.com>
In-Reply-To:
 <SYXPR01MB0463ECF852AA9D4DB30D0841C50F0@SYXPR01MB0463.ausprd01.prod.outlook.com>
Accept-Language: en-AU, en-US
Content-Language: en-US
X-Hashtags: #Newsletters
X-MS-Has-Attach: yes
X-MS-TNEF-Correlator:
authentication-results: spf=none (sender IP is )
 smtp.mailfrom=reply@nucleusnetwork.com.au; 
x-ms-exchange-messagesentrepresentingtype: 1
x-originating-ip: [49.255.134.62]
x-ms-publictraffictype: Email
x-microsoft-exchange-diagnostics:
 1;SYXPR01MB1566;6:6LeE8jZR1RdWMn4Og+ykA+LNn4noShlzzfzwtvda9s0LwKEyctp34iZHXKc35nmMQQzqYvd2Wrjm3GDZ/FIh9QAoX3gcyU95kZRl07l/EP0mgzDNXZYiX5X7ipydMM4A5KBBBfnM25WPwAopox549NaO8lxiUw8ej3BV2r6X+04AowOgHRS8WJIWma5ayW8QaVHjuvfZ/MOM39Ydl1EAG55hGEY83a0mLESq1jAZ35cSmCyYnImXs9kWEb+fsWxyv6+7bO13omogWzjFcT1WuYbgKb8ey6bPvsUsBNOWIVzHLtwwTHNuKGtRoL0MJy5E4YwKi1pzqKSnITavb3RfywPtwoCvvQrYvHyeBah5HKP0lMSFq4D14XavM+f3B1ZkFgncryTLnrhHvxMUfDmv0ESldBuAPVuapOmIt11VaZ5zW3kH3SRG2goN+PAEN5tmlBLf5jkh7Aws+GKlVYCL9g==;5:C4ghbbXzX1FRCpBrS6RYXlfGYgrdTkrvPglzaNd0rFFNq38L/ck2/msU25T/+0qrus0UgnmR+qlRn7O/53LY7sJ1JuDwuFGVX/KyWfUQzj1TEfsXOAll6aMsQ/hQk9E5YCM8gOYAE3hUwSDkdTrl45rLp8ZyK+naLpsVmeJNLDA=;7:BLc2aLqcdgINOOFkq8hndYUe56/Syeh2iM8SdLCpycql+S6TpOQ7fL+pIE/G8mphWJI/cJgTYCUiVkT7CImmJxbAo6/pNH4ByI0xvUk1B9QrSrdScxAJSRdngMjSx1f6N1+na1UVrOXnNWmnBF6Govy4uS4j7LoXxCZdKN7G8EUzMoHbXjr8u+olZR/Wn2EB4y9zl7uTF+Ihbg8kiPaRml/lLsgr74c3RLfxcCgGX2qlReemKSrX3+2wk7uFs1Df
x-ms-office365-filtering-correlation-id: ac25448a-ef91-45a0-1322-08d60f9e28c7
x-microsoft-antispam:
 BCL:0;PCL:0;RULEID:(7020095)(4652040)(8989137)(4534165)(4627221)(201703031133081)(201702281549075)(8990107)(5600074)(711020)(2017052603328)(7153060)(49563074)(7193020);SRVR:SYXPR01MB1566;
x-ms-traffictypediagnostic: SYXPR01MB1566:
x-ms-exchange-sharedmailbox-routingagent-processed: True
x-microsoft-antispam-prvs:
 <SYXPR01MB1566187163AA06907232F997F40E0@SYXPR01MB1566.ausprd01.prod.outlook.com>
x-exchange-antispam-report-test:
 UriScan:(28532068793085)(148322886591682)(277860510277777)(28212336023702)(31418570063057)(277809949798613)(254730959083279)(86561027422486)(81227570615382)(46150409022019);
x-ms-exchange-senderadcheck: 1
x-exchange-antispam-report-cfa-test:
 BCL:0;PCL:0;RULEID:(8211001083)(102415395)(6040522)(2401047)(5005006)(8121501046)(93006095)(93001095)(10201501046)(3002001)(3231311)(944501410)(52105095)(149027)(150027)(6041310)(201703131423095)(201702281528075)(20161123555045)(201703061421075)(201703061406153)(20161123562045)(20161123564045)(20161123560045)(20161123558120)(201708071742011)(7699016);SRVR:SYXPR01MB1566;BCL:0;PCL:0;RULEID:;SRVR:SYXPR01MB1566;
x-forefront-prvs: 0782EC617F
x-forefront-antispam-report:
 SFV:NSPM;SFS:(10019020)(1496009)(39850400004)(396003)(376002)(346002)(136003)(366004)(199004)(189003)(9763003)(76576003)(478600001)(476003)(88732003)(316002)(26005)(89122003)(446003)(5250100002)(486006)(65686004)(11346002)(6116002)(790700001)(14454004)(76176011)(186003)(106356001)(2906002)(86362001)(105586002)(3846002)(2420400007)(99286004)(7696005)(15650500001)(881003)(99936001)(7110500001)(7336002)(7276002)(39060400002)(66066001)(7366002)(7416002)(10126004)(102836004)(7406005)(8936002)(68770200003)(256004)(53936002)(25786009)(74316002)(54556002)(9686003)(7736002)(54896002)(6306002)(55016002)(2900100001)(733005)(6506007)(97736004)(6436002)(8676002)(33656002)(93886005)(68736007)(1671002)(81156014)(19627405001)(74482002)(5660300001)(606006)(81166006)(6666003)(7066003)(109986005)(236005)(15398625002);DIR:OUT;SFP:1102;SCL:1;SRVR:SYXPR01MB1566;H:SYXPR01MB0463.ausprd01.prod.outlook.com;FPR:;SPF:None;LANG:en;PTR:InfoNoRecords;A:1;MX:1;
received-spf: None (protection.outlook.com: nucleusnetwork.com.au does not
 designate permitted sender hosts)
x-microsoft-antispam-message-info:
 vOG1XIr414+ElQb4wUmyWUbBCm0u7BTcaurB/iU9VReFBRcqkj7q2vj4ut+F/ZAye7Paf+KtFvMpKKL3Gn5/7Ra2pY54zDENnXEdIEr7hCG+fnjNLmkH5G/THoMn2khfY4Du017rFE+PFSZp8IMSGvMhD5wnGxifvl1kV8mVmXrxIIpe7Ecqrrh4kpdeeMSkwBu+7srqcZihxN8wrH+SDmNFuTkoIKzH5wcs/b9lLGDuG2kshKmTHZgiWiXmpOVoel3Bq8/twcCijGBnNB5D34Dg2/+0q7IFmMkbNkOY5H9j0kOiVZ2SdmaQSvl4e7QWcmkAuIspzelUpPFBmPsCI0frmiQJi27yDO4AqykSLXU=
spamdiagnosticoutput: 1:99
spamdiagnosticmetadata: NSPM
Content-Type: multipart/related;
	boundary="_007_SYXPR01MB0463964C2DD1263171DC8222C50E0SYXPR01MB0463ausp_";
	type="multipart/alternative"
MIME-Version: 1.0
X-OriginatorOrg: nucleusnetwork.com.au
X-MS-Exchange-CrossTenant-Network-Message-Id: ac25448a-ef91-45a0-1322-08d60f9e28c7
X-MS-Exchange-CrossTenant-originalarrivaltime: 01 Sep 2018 00:01:43.1089
 (UTC)
X-MS-Exchange-CrossTenant-fromentityheader: Hosted
X-MS-Exchange-CrossTenant-id: 789e47a3-a852-4653-860e-4105eaf939ce
X-MS-Exchange-Transport-CrossTenantHeadersStamped: SYXPR01MB1566
X-TUID: HbB65AkMD/3n

--_007_SYXPR01MB0463964C2DD1263171DC8222C50E0SYXPR01MB0463ausp_
Content-Type: multipart/alternative;
	boundary="_000_SYXPR01MB0463964C2DD1263171DC8222C50E0SYXPR01MB0463ausp_"

--_000_SYXPR01MB0463964C2DD1263171DC8222C50E0SYXPR01MB0463ausp_
Content-Type: text/plain; charset="iso-2022-jp"
Content-Transfer-Encoding: quoted-printable





centrefor
clinicalstudies

It=1B$B!G=1B(Bs that time of the week again! Finding the perfect study has =
never been easier, check out the categories below and follow the link for m=
ore information.

To register your interest, simply respond to this email or feel free to giv=
e our friendly Recruitment team a call on 1800 243 733.


LAST CHANCE
***TGIF***
$1,950
The TGIF Study will be looking at a previously tested and well tolerated do=
se of medication. This same medication has been trialled in the past here a=
t the Centre for Clinical Studies.

CLICK HERE<http://clinicalstudies.com.au/wp-content/uploads/2018/08/PRAX-IC=
3-MUG-3.pdf?utm_source=3Doutlook&utm_campaign=3DOM-feature-1-PRAX-AUS-1001>=
 for more information

LAST CHANCE
***3 NIGHT STAY STUDY***
$1,050
This study is investigating a potential treatment for patients with moderat=
e to severe asthma. Asthma is a chronic respiratory condition that can invo=
lve swelling in the lungs, mucus build-up and obstruction of the airways.

CLICK HERE<http://clinicalstudies.com.au/wp-content/uploads/2018/08/3-NIGHT=
-STAY-STUDY-SAD-c9ROC.pdf?utm_source=3Doutlook&utm_campaign=3DOM-feature-2-=
PRS-060-PCS_06_17> for more information


5 STAR STUDIES
Yes, you heard us! 5 =1B$B!z=1B(B studies. These amazing studies are carefu=
lly selected individually based on participant preference and study schedul=
e.
CLICK HERE<http://clinicalstudies.com.au/wp-content/uploads/2018/08/5SS_MAL=
ES_1-2SEP.pdf?utm_source=3Doutlook&utm_campaign=3DOM-five-star-studies> for=
 more information

NEW STUDIES
After some new studies? Check it out below!
CLICK HERE<http://clinicalstudies.com.au/wp-content/uploads/2018/08/NEW_STU=
DIES_MALES_1-2SEP.pdf?utm_source=3Doutlook&utm_campaign=3DOM-new-studies> f=
or more information

QUICK & EASY
Looking for something that quick and easy- done within a short period? Chec=
k these studies out
CLICK HERE<http://clinicalstudies.com.au/wp-content/uploads/2018/08/QE_OM_1=
SEP.pdf?utm_source=3Doutlook&utm_campaign=3DOM-quick-and-easy> for more inf=
ormation


HIGH REIMBURSEMENT
These studies are typically longer in duration with a larger time commitmen=
t.
CLICK HERE<http://clinicalstudies.com.au/wp-content/uploads/2018/08/OM-HR-0=
1.09.2018.pdf?utm_source=3Doutlook&utm_campaign=3DOM-high-reimbursement> fo=
r more information

NOT YOUR TYPICAL STUDIES
Looking for something different? These studies are a little bit special.
CLICK HERE<http://clinicalstudies.com.au/wp-content/uploads/2018/08/OM-NYTS=
-01.09.2018.pdf?utm_source=3Doutlook&utm_campaign=3DOM-not-your-typical-stu=
dy> for more information


SOME THINGS YOU MIGHT WANT TO KNOW ABOUT US

If you=1B$B!G=1B(Bre wondering where we are, just view our handy map<http:/=
/clinicalstudies.com.au/wp-content/uploads/2018/05/How-to-get-to-CFCS.pdf>

Let us walk you through the Participant Journey<https://clinicalstudies.com=
.au/participants-journey/>

Spare time? Check out our awesome blog<https://clinicalstudies.com.au/blog/=
>

Hear what our amazing volunteers have to say in their testimonials<https://=
clinicalstudies.com.au/testimonial/>!


Don=1B$B!G=1B(Bt forget, we=1B$B!G=1B(Bre also offering

$100 TO REFER A FRIEND!
Check out our Terms and Conditions<http://clinicalstudies.com.au/wp-content=
/uploads/2017/12/Referral-Terms-and-Conditions.pdf>
Kind regards,

Recruitment Team

Centre for Clinical Studies
Office: | Level 5 Burnet Institute | AMREP Precinct | 89 Commercial Road | =
Victoria 3004 | Australia
T: 1800 243 733 | Reception: 03 9076 8957
reply@nucleusnetwork.com.au<mailto:reply@nucleusnetwork.com.au> | www.clini=
calstudies.com.au<http://www.clinicalstudies.com.au/>
Nucleus Network, Australia's Clinical Research Centre, operates in associat=
ion with Centre for Clinical Studies, Clinical Trials Consulting and its ne=
twork partners
1800 243 733

[cid:image002.png@01D244DB.B31610A0]<https://www.facebook.com/CfCStudies/> =
 [cid:image004.png@01D244DB.B31610A0] <https://www.instagram.com/centreforc=
linicalstudies/>   [cid:image005.png@01D244DB.B31610A0] <https://twitter.co=
m/cfcstudies>   [cid:image010.png@01D244DB.B31610A0] <https://www.youtube.c=
om/channel/UCxWbVDcH-sfT8zaZA4uvQQw>
Find us on Facebook, Instagram, Twitter and YouTube

If you do not wish to receive any further emails from us then please reply =
to this email with the word =1B$B!F=1B(BUNSUBSCRIBE=1B$B!G=1B(B in the subj=
ect box.





To stop receiving messages from Recruitment Team Members<https://outlook.of=
fice365.com/owa/recruitmentteammembers@nucleusnetwork.com.au/groupsubscript=
ion.ashx?realm=3Dnucleusnetwork.com.au&source=3DEscalatedMessage&action=3Dc=
onversations> group, stop following it<https://outlook.office365.com/owa/re=
cruitmentteammembers@nucleusnetwork.com.au/groupsubscription.ashx?realm=3Dn=
ucleusnetwork.com.au&source=3DEscalatedMessage&action=3Dunsubscribe>.





--_000_SYXPR01MB0463964C2DD1263171DC8222C50E0SYXPR01MB0463ausp_
Content-Type: text/html; charset="iso-2022-jp"
Content-Transfer-Encoding: quoted-printable

<html xmlns:v=3D"urn:schemas-microsoft-com:vml" xmlns:o=3D"urn:schemas-micr=
osoft-com:office:office" xmlns:w=3D"urn:schemas-microsoft-com:office:word" =
xmlns:x=3D"urn:schemas-microsoft-com:office:excel" xmlns:m=3D"http://schema=
s.microsoft.com/office/2004/12/omml" xmlns=3D"http://www.w3.org/TR/REC-html=
40">
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3Diso-2022-=
jp">
<meta name=3D"Generator" content=3D"Microsoft Word 15 (filtered medium)">
<!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0cm;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-fareast-language:EN-US;}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	color:#0563C1;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-priority:99;
	color:#954F72;
	text-decoration:underline;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{mso-style-priority:1;
	margin:0cm;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-fareast-language:JA;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-fareast-language:EN-US;}
p.msonormal0, li.msonormal0, div.msonormal0
	{mso-style-name:msonormal;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-fareast-language:JA;}
span.EmailStyle20
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle21
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle22
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle23
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle24
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle25
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle26
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle27
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle28
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle29
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle30
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle31
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle32
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle33
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle34
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle35
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle36
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle37
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle38
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle39
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle40
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle41
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle42
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle43
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle44
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle45
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle46
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle47
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle48
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle49
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle50
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle51
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle52
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle53
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle54
	{mso-style-type:personal;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.EmailStyle55
	{mso-style-type:personal-reply;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
.MsoChpDefault
	{mso-style-type:export-only;
	font-size:10.0pt;}
@page WordSection1
	{size:612.0pt 792.0pt;
	margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
	{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext=3D"edit" spidmax=3D"1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext=3D"edit">
<o:idmap v:ext=3D"edit" data=3D"1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang=3D"EN-AU" link=3D"#0563C1" vlink=3D"#954F72">
<div class=3D"WordSection1">
<p class=3D"MsoNormal"><o:p>&nbsp;</o:p></p>
<p class=3D"MsoNormal"><o:p>&nbsp;</o:p></p>
<p class=3D"MsoNormal"><span style=3D"color:#C00000"><o:p>&nbsp;</o:p></spa=
n></p>
<p class=3D"MsoNormal"><span style=3D"font-size:1.0pt;color:white"><o:p>&nb=
sp;</o:p></span></p>
<table class=3D"MsoNormalTable" border=3D"0" cellspacing=3D"0" cellpadding=
=3D"0" style=3D"border-collapse:collapse">
<tbody>
<tr style=3D"height:33.55pt">
<td width=3D"557" valign=3D"top" style=3D"width:417.8pt;padding:0cm 5.4pt 0=
cm 5.4pt;height:33.55pt">
<p class=3D"MsoNormal"><b><span lang=3D"EN-US" style=3D"font-size:18.0pt;fo=
nt-family:&quot;Neue Haas Grotesk Text Pro&quot;,sans-serif;color:#4B54FF">=
centre</span></b><span lang=3D"EN-US" style=3D"font-size:18.0pt;font-family=
:&quot;Neue Haas Grotesk Text Pro&quot;,sans-serif;color:#4B54FF">for<b><o:=
p></o:p></b></span></p>
<p class=3D"MsoNormal"><b><span lang=3D"EN-US" style=3D"font-size:18.0pt;fo=
nt-family:&quot;Neue Haas Grotesk Text Pro&quot;,sans-serif;color:#4B54FF">=
clinical</span></b><span lang=3D"EN-US" style=3D"font-size:18.0pt;font-fami=
ly:&quot;Neue Haas Grotesk Text Pro&quot;,sans-serif;color:#4B54FF">studies=
<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span style=3D"font-size:12.0pt"><br>
It=1B$B!G=1B(Bs that time of the week again! Finding the perfect study has =
never been easier, check out the categories below and follow the link for m=
ore information.<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span style=3D"font-size:12.0pt"><o:p>&nbsp;</o:p></=
span></p>
<p class=3D"MsoNormal"><span style=3D"font-size:12.0pt">To register your in=
terest, simply respond to this email or feel free to give our friendly Recr=
uitment team a call on
<b><u>1800 243 733</u></b>. &nbsp;<o:p></o:p></span></p>
</td>
</tr>
</tbody>
</table>
<p class=3D"MsoNormal"><o:p>&nbsp;</o:p></p>
<table class=3D"MsoNormalTable" border=3D"0" cellspacing=3D"0" cellpadding=
=3D"0" style=3D"border-collapse:collapse">
<tbody>
<tr>
<td width=3D"367" valign=3D"top" style=3D"width:275.3pt;border:solid white =
2.25pt;border-bottom:solid white 6.0pt;background:#E75A57;padding:0cm 5.4pt=
 0cm 5.4pt">
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center"><b><spa=
n style=3D"font-size:20.0pt">LAST CHANCE<br>
</span></b><b><span style=3D"font-size:22.0pt;color:white">***TGIF***</span=
></b><b><span style=3D"font-size:20.0pt;color:white"><o:p></o:p></span></b>=
</p>
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center"><b><spa=
n style=3D"font-size:18.0pt;color:white">$1,950<o:p></o:p></span></b></p>
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center"><b><spa=
n style=3D"color:white">The TGIF Study will be looking at a previously test=
ed and well tolerated dose of medication. This same medication has been tri=
alled in the past here at the Centre for
 Clinical Studies. &nbsp;</span><o:p></o:p></b></p>
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center"><b><o:p=
>&nbsp;</o:p></b></p>
<p class=3D"MsoNormal" align=3D"center" style=3D"margin-bottom:12.0pt;text-=
align:center">
<b><a href=3D"http://clinicalstudies.com.au/wp-content/uploads/2018/08/PRAX=
-IC3-MUG-3.pdf?utm_source=3Doutlook&amp;utm_campaign=3DOM-feature-1-PRAX-AU=
S-1001">CLICK HERE</a><span style=3D"color:white"> for more information</sp=
an><o:p></o:p></b></p>
</td>
<td width=3D"378" valign=3D"top" style=3D"width:10.0cm;border-top:solid whi=
te 2.25pt;border-left:none;border-bottom:solid white 6.0pt;border-right:sol=
id white 2.25pt;background:#E75A57;padding:0cm 0cm 0cm 0cm">
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center"><b><spa=
n style=3D"font-size:20.0pt">LAST CHANCE<br>
</span></b><b><span style=3D"font-size:22.0pt;color:white">***3 NIGHT STAY =
STUDY***</span></b><b><span style=3D"font-size:20.0pt;color:white"><o:p></o=
:p></span></b></p>
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center"><b><spa=
n style=3D"font-size:18.0pt;color:white">$1,050<o:p></o:p></span></b></p>
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center"><b><spa=
n style=3D"color:white">This study is investigating a potential treatment f=
or patients with moderate to severe asthma. Asthma is a chronic respiratory=
 condition that can involve swelling in
 the lungs, mucus build-up and obstruction of the airways.</span></b><b><sp=
an style=3D"font-size:10.0pt;color:white"><o:p></o:p></span></b></p>
<p class=3D"MsoNormal"><b><o:p>&nbsp;</o:p></b></p>
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center"><b><a h=
ref=3D"http://clinicalstudies.com.au/wp-content/uploads/2018/08/3-NIGHT-STA=
Y-STUDY-SAD-c9ROC.pdf?utm_source=3Doutlook&amp;utm_campaign=3DOM-feature-2-=
PRS-060-PCS_06_17">CLICK HERE</a><span style=3D"color:white">
 for more information</span></b><b><span style=3D"font-size:8.0pt;color:bla=
ck"><o:p></o:p></span></b></p>
</td>
</tr>
<tr>
<td width=3D"745" colspan=3D"2" valign=3D"top" style=3D"width:558.8pt;borde=
r:solid white 2.25pt;border-top:none;background:#A7ABFF;padding:0cm 5.4pt 0=
cm 5.4pt">
<p class=3D"MsoNormal" align=3D"center" style=3D"margin-bottom:12.0pt;text-=
align:center">
<b><span style=3D"font-size:8.0pt"><br>
</span></b><b><span style=3D"font-size:16.0pt">5 STAR STUDIES </span></b><b=
r>
<strong><span style=3D"font-size:12.0pt;font-family:&quot;Calibri&quot;,san=
s-serif;font-weight:normal">Yes, you heard us! 5
</span></strong><strong><span style=3D"font-size:12.0pt;font-family:&quot;S=
egoe UI Symbol&quot;,sans-serif;font-weight:normal">=1B$B!z=1B(B</span></st=
rong><strong><span style=3D"font-size:12.0pt;font-family:&quot;Calibri&quot=
;,sans-serif;font-weight:normal"> studies. These amazing studies are
 carefully selected individually based on participant preference and study =
schedule.</span></strong><span style=3D"color:#F2F2F2"><br>
</span><b><a href=3D"http://clinicalstudies.com.au/wp-content/uploads/2018/=
08/5SS_MALES_1-2SEP.pdf?utm_source=3Doutlook&amp;utm_campaign=3DOM-five-sta=
r-studies">CLICK HERE</a> for more information</b><b><span style=3D"font-si=
ze:12.0pt;color:black"><o:p></o:p></span></b></p>
</td>
</tr>
<tr>
<td width=3D"745" colspan=3D"2" valign=3D"top" style=3D"width:558.8pt;borde=
r:solid white 2.25pt;border-top:none;background:#979CFF;padding:0cm 5.4pt 0=
cm 5.4pt">
<p class=3D"MsoNormal" align=3D"center" style=3D"margin-bottom:12.0pt;text-=
align:center">
<b><span style=3D"font-size:16.0pt">NEW STUDIES </span></b><br>
After some new studies? Check it out below!<span style=3D"color:#F2F2F2"><b=
r>
</span><b><a href=3D"http://clinicalstudies.com.au/wp-content/uploads/2018/=
08/NEW_STUDIES_MALES_1-2SEP.pdf?utm_source=3Doutlook&amp;utm_campaign=3DOM-=
new-studies">CLICK HERE</a> for more information<o:p></o:p></b></p>
</td>
</tr>
<tr>
<td width=3D"745" colspan=3D"2" valign=3D"top" style=3D"width:558.8pt;borde=
r:solid white 2.25pt;border-top:none;background:#B7BAFF;padding:0cm 5.4pt 0=
cm 5.4pt">
<p class=3D"MsoNormal" align=3D"center" style=3D"margin-bottom:16.0pt;text-=
align:center">
<b><span style=3D"font-size:16.0pt">QUICK &amp; EASY </span></b><br>
<span style=3D"color:black">Looking for something that quick and easy- done=
 within a short period? Check these studies out</span><span style=3D"color:=
#002060"><br>
</span><b><a href=3D"http://clinicalstudies.com.au/wp-content/uploads/2018/=
08/QE_OM_1SEP.pdf?utm_source=3Doutlook&amp;utm_campaign=3DOM-quick-and-easy=
">CLICK HERE</a> for more information</b><b><span style=3D"font-size:8.0pt"=
><o:p></o:p></span></b></p>
</td>
</tr>
<tr>
<td width=3D"745" colspan=3D"2" valign=3D"top" style=3D"width:558.8pt;borde=
r:solid white 2.25pt;border-top:none;background:#979CFF;padding:0cm 5.4pt 0=
cm 5.4pt">
<p class=3D"MsoNormal" align=3D"center" style=3D"margin-bottom:12.0pt;text-=
align:center">
<b><span style=3D"font-size:8.0pt"><br>
</span></b><b><span style=3D"font-size:16.0pt">HIGH REIMBURSEMENT</span></b=
><br>
<strong><span style=3D"font-size:12.0pt;font-family:&quot;Calibri&quot;,san=
s-serif;color:black;font-weight:normal">These studies are typically longer =
in duration with a larger time commitment.</span></strong><span style=3D"co=
lor:#F2F2F2"><br>
</span><b><a href=3D"http://clinicalstudies.com.au/wp-content/uploads/2018/=
08/OM-HR-01.09.2018.pdf?utm_source=3Doutlook&amp;utm_campaign=3DOM-high-rei=
mbursement">CLICK HERE</a> for more information</b><b><span style=3D"font-s=
ize:8.0pt"><o:p></o:p></span></b></p>
</td>
</tr>
<tr>
<td width=3D"745" colspan=3D"2" valign=3D"top" style=3D"width:558.8pt;borde=
r-top:none;border-left:solid white 2.25pt;border-bottom:solid white 3.0pt;b=
order-right:solid white 2.25pt;background:#B7BAFF;padding:0cm 5.4pt 0cm 5.4=
pt">
<p class=3D"MsoNormal" align=3D"center" style=3D"margin-bottom:12.0pt;text-=
align:center">
<b><span style=3D"font-size:16.0pt">NOT YOUR TYPICAL STUDIES</span></b><br>
<strong><span style=3D"font-family:&quot;Calibri&quot;,sans-serif;font-weig=
ht:normal">Looking for something different? These studies are a little bit =
special.</span></strong><span style=3D"color:red"><br>
</span><b><a href=3D"http://clinicalstudies.com.au/wp-content/uploads/2018/=
08/OM-NYTS-01.09.2018.pdf?utm_source=3Doutlook&amp;utm_campaign=3DOM-not-yo=
ur-typical-study">CLICK HERE</a> for more information<o:p></o:p></b></p>
</td>
</tr>
</tbody>
</table>
<p class=3D"MsoNormal"><o:p>&nbsp;</o:p></p>
<table class=3D"MsoNormalTable" border=3D"0" cellspacing=3D"0" cellpadding=
=3D"0" style=3D"border-collapse:collapse">
<tbody>
<tr style=3D"height:27.65pt">
<td width=3D"557" style=3D"width:417.8pt;border:solid white 1.0pt;backgroun=
d:#3B3838;padding:0cm 5.4pt 0cm 5.4pt;height:27.65pt">
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center"><b><spa=
n style=3D"font-size:14.0pt;color:white">SOME THINGS YOU MIGHT WANT TO KNOW=
 ABOUT US<o:p></o:p></span></b></p>
</td>
</tr>
<tr>
<td width=3D"557" style=3D"width:417.8pt;border:solid white 1.0pt;border-to=
p:none;background:#949494;padding:0cm 5.4pt 0cm 5.4pt">
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center">If you=
=1B$B!G=1B(Bre wondering where we are, just view our handy
<a href=3D"http://clinicalstudies.com.au/wp-content/uploads/2018/05/How-to-=
get-to-CFCS.pdf">
map</a><o:p></o:p></p>
</td>
</tr>
<tr>
<td width=3D"557" style=3D"width:417.8pt;border:solid white 1.0pt;border-to=
p:none;background:#A6A6A6;padding:0cm 5.4pt 0cm 5.4pt">
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center">Let us =
walk you through the
<a href=3D"https://clinicalstudies.com.au/participants-journey/">Participan=
t Journey</a><o:p></o:p></p>
</td>
</tr>
<tr>
<td width=3D"557" style=3D"width:417.8pt;border:solid white 1.0pt;border-to=
p:none;background:#BFBFBF;padding:0cm 5.4pt 0cm 5.4pt">
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center">Spare t=
ime? Check out our awesome
<a href=3D"https://clinicalstudies.com.au/blog/">blog</a><o:p></o:p></p>
</td>
</tr>
<tr style=3D"height:4.35pt">
<td width=3D"557" style=3D"width:417.8pt;border:solid white 1.0pt;border-to=
p:none;background:#D9D9D9;padding:0cm 5.4pt 0cm 5.4pt;height:4.35pt">
<p class=3D"MsoNormal" align=3D"center" style=3D"text-align:center">Hear wh=
at our amazing volunteers have to say in their
<a href=3D"https://clinicalstudies.com.au/testimonial/">testimonials</a>!<o=
:p></o:p></p>
</td>
</tr>
</tbody>
</table>
<p class=3D"MsoNormal"><o:p>&nbsp;</o:p></p>
<p class=3D"MsoNormal"><b>Don=1B$B!G=1B(Bt forget, we=1B$B!G=1B(Bre also of=
fering<o:p></o:p></b></p>
<p class=3D"MsoNoSpacing" style=3D"margin-bottom:12.0pt"><strong><span styl=
e=3D"font-size:22.0pt;font-family:&quot;Calibri&quot;,sans-serif;color:#4B5=
4FF">$100</span></strong><b><span style=3D"font-size:22.0pt;color:#4B54FF">
<strong><span style=3D"font-family:&quot;Calibri&quot;,sans-serif">TO REFER=
 A&nbsp;FRIEND!</span></strong></span></b><u><span style=3D"color:black"><b=
r>
</span></u><b>Check out our </b><a href=3D"http://clinicalstudies.com.au/wp=
-content/uploads/2017/12/Referral-Terms-and-Conditions.pdf"><b>Terms and Co=
nditions</b></a><o:p></o:p></p>
<p class=3D"MsoNormal">Kind regards,<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p>&nbsp;</o:p></p>
<p class=3D"MsoNormal"><b><span style=3D"font-size:22.0pt;font-family:&quot=
;Monotype Corsiva&quot;;mso-fareast-language:EN-AU">Recruitment Team<o:p></=
o:p></span></b></p>
<p class=3D"MsoNormal"><span style=3D"font-family:&quot;Arial&quot;,sans-se=
rif;color:#1F497D;mso-fareast-language:EN-AU"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><b><span style=3D"color:#00B0F0;mso-fareast-language=
:EN-AU">Centre for Clinical Studies</span></b><span style=3D"color:#99CC00;=
mso-fareast-language:EN-AU">
</span><span style=3D"color:#1F497D;mso-fareast-language:EN-AU"><br>
Office: | Level 5 Burnet Institute | AMREP Precinct | 89 Commercial Road |&=
nbsp;Victoria 3004 | Australia<br>
T: </span><span style=3D"color:#1F4E79;mso-fareast-language:EN-AU">1800 243=
 733 |&nbsp;</span><span style=3D"color:#1F497D;mso-fareast-language:EN-AU"=
>Reception: 03 9076 8957
<o:p></o:p></span></p>
<p class=3D"MsoNormal"><a href=3D"mailto:reply@nucleusnetwork.com.au"><span=
 style=3D"mso-fareast-language:EN-AU">reply@nucleusnetwork.com.au</span></a=
><span style=3D"mso-fareast-language:EN-AU"> |
</span><a href=3D"http://www.clinicalstudies.com.au/"><b><span lang=3D"FR" =
style=3D"color:#00B0F0;mso-fareast-language:EN-AU">www.clinicalstudies.com.=
au</span></b></a><b><span lang=3D"FR" style=3D"color:#00B0F0;mso-fareast-la=
nguage:EN-AU"><o:p></o:p></span></b></p>
<p class=3D"MsoNormal"><b><i><span style=3D"color:#1F497D;mso-fareast-langu=
age:EN-AU">Nucleus Network, Australia's Clinical Research Centre, operates =
in association with Centre for Clinical Studies, Clinical Trials Consulting=
 and its network partners<o:p></o:p></span></i></b></p>
<p class=3D"MsoNormal"><b><span style=3D"font-size:24.0pt;color:black;mso-f=
areast-language:EN-AU">1800 243 733</span></b><span style=3D"color:black;ms=
o-fareast-language:EN-AU"><o:p></o:p></span></p>
<p class=3D"MsoNormal"><span style=3D"mso-fareast-language:EN-AU"><o:p>&nbs=
p;</o:p></span></p>
<p class=3D"MsoNormal"><a href=3D"https://www.facebook.com/CfCStudies/"><sp=
an style=3D"color:#1F497D;mso-fareast-language:EN-AU;text-decoration:none">=
<img border=3D"0" width=3D"37" height=3D"37" style=3D"width:.3854in;height:=
.3854in" id=3D"Picture_x0020_10" src=3D"cid:image001.png@01D43BD2.7FC365F0"=
 alt=3D"cid:image002.png@01D244DB.B31610A0"></span></a><span style=3D"color=
:#1F497D;mso-fareast-language:EN-AU">&nbsp;
</span><a href=3D"https://www.instagram.com/centreforclinicalstudies/"><spa=
n style=3D"color:#1F497D;mso-fareast-language:EN-AU;text-decoration:none"><=
img border=3D"0" width=3D"37" height=3D"37" style=3D"width:.3854in;height:.=
3854in" id=3D"Picture_x0020_15" src=3D"cid:image002.png@01D43BD2.7FC365F0" =
alt=3D"cid:image004.png@01D244DB.B31610A0"></span></a><span style=3D"color:=
#1F497D;mso-fareast-language:EN-AU">&nbsp;&nbsp;</span><a href=3D"https://t=
witter.com/cfcstudies"><span style=3D"color:#1F497D;mso-fareast-language:EN=
-AU;text-decoration:none"><img border=3D"0" width=3D"37" height=3D"37" styl=
e=3D"width:.3854in;height:.3854in" id=3D"Picture_x0020_9" src=3D"cid:image0=
03.png@01D43BD2.7FC365F0" alt=3D"cid:image005.png@01D244DB.B31610A0"></span=
></a><span style=3D"color:#1F497D;mso-fareast-language:EN-AU">&nbsp;&nbsp;<=
/span><a href=3D"https://www.youtube.com/channel/UCxWbVDcH-sfT8zaZA4uvQQw">=
<span style=3D"color:#1F497D;mso-fareast-language:EN-AU;text-decoration:non=
e"><img border=3D"0" width=3D"37" height=3D"37" style=3D"width:.3854in;heig=
ht:.3854in" id=3D"Picture_x0020_13" src=3D"cid:image004.png@01D43BD2.7FC365=
F0" alt=3D"cid:image010.png@01D244DB.B31610A0"></span></a><span style=3D"co=
lor:#1F497D;mso-fareast-language:EN-AU">&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p>=
</span></p>
<p class=3D"MsoNormal"><span style=3D"font-size:9.0pt;mso-fareast-language:=
EN-AU">Find us on Facebook, Instagram, Twitter and YouTube<o:p></o:p></span=
></p>
<p class=3D"MsoNormal"><span style=3D"mso-fareast-language:EN-AU"><o:p>&nbs=
p;</o:p></span></p>
<p class=3D"MsoNormal"><span style=3D"font-size:9.0pt">If you do not wish t=
o receive any further emails from us then please reply to this email with t=
he word =1B$B!F=1B(BUNSUBSCRIBE=1B$B!G=1B(B in the subject box.</span><span=
 style=3D"font-size:12.0pt;color:#003F80"><o:p></o:p></span></p>
<div id=3D"a59ada49-a492-4f1d-ac57-74be3a4194fc">
<table class=3D"MsoNormalTable" border=3D"0" cellspacing=3D"0" cellpadding=
=3D"0" width=3D"50" style=3D"width:37.5pt">
<tbody>
<tr style=3D"height:13.5pt">
<td style=3D"border:none;border-bottom:solid #EAEAEA 1.0pt;padding:0cm 0cm =
0cm 0cm;height:13.5pt">
<p class=3D"MsoNormal"><span style=3D"mso-fareast-language:EN-AU">&nbsp;<o:=
p></o:p></span></p>
</td>
</tr>
</tbody>
</table>
<p class=3D"MsoNormal"><span style=3D"display:none;mso-fareast-language:EN-=
AU"><o:p>&nbsp;</o:p></span></p>
<table class=3D"MsoNormalTable" border=3D"0" cellspacing=3D"0" cellpadding=
=3D"0" width=3D"90%" style=3D"width:90.0%">
<tbody>
<tr style=3D"height:12.75pt">
<td style=3D"padding:0cm 0cm 0cm 0cm;height:12.75pt">
<p class=3D"MsoNormal" style=3D"line-height:12.75pt"><span style=3D"mso-far=
east-language:EN-AU">&nbsp;<o:p></o:p></span></p>
</td>
</tr>
<tr>
<td style=3D"padding:0cm 0cm 0cm 0cm">
<p class=3D"MsoNormal" style=3D"line-height:12.75pt"><span style=3D"font-si=
ze:9.0pt;font-family:&quot;Segoe UI&quot;,sans-serif;color:#666666;mso-fare=
ast-language:EN-AU">To stop receiving messages from
<a href=3D"https://outlook.office365.com/owa/recruitmentteammembers@nucleus=
network.com.au/groupsubscription.ashx?realm=3Dnucleusnetwork.com.au&amp;sou=
rce=3DEscalatedMessage&amp;action=3Dconversations">
<span style=3D"font-family:&quot;Segoe UI Semibold&quot;,sans-serif;color:#=
0072C6;text-decoration:none">Recruitment Team Members</span></a> group,
<a href=3D"https://outlook.office365.com/owa/recruitmentteammembers@nucleus=
network.com.au/groupsubscription.ashx?realm=3Dnucleusnetwork.com.au&amp;sou=
rce=3DEscalatedMessage&amp;action=3Dunsubscribe">
<span style=3D"font-family:&quot;Segoe UI Semibold&quot;,sans-serif;color:#=
0072C6;text-decoration:none">stop following it</span></a>.<o:p></o:p></span=
></p>
</td>
</tr>
<tr style=3D"height:12.75pt">
<td style=3D"padding:0cm 0cm 0cm 0cm;height:12.75pt">
<p class=3D"MsoNormal" style=3D"line-height:12.75pt"><span style=3D"mso-far=
east-language:EN-AU">&nbsp;<o:p></o:p></span></p>
</td>
</tr>
</tbody>
</table>
<p class=3D"MsoNormal"><span style=3D"mso-fareast-language:EN-AU"><o:p>&nbs=
p;</o:p></span></p>
</div>
</div>
</body>
</html>

--_000_SYXPR01MB0463964C2DD1263171DC8222C50E0SYXPR01MB0463ausp_--

--_007_SYXPR01MB0463964C2DD1263171DC8222C50E0SYXPR01MB0463ausp_
Content-Type: image/png; name="image001.png"
Content-Description: image001.png
Content-Disposition: inline; filename="image001.png"; size=802;
	creation-date="Fri, 24 Aug 2018 07:47:19 GMT";
	modification-date="Fri, 24 Aug 2018 07:47:19 GMT"
Content-ID: <image001.png@01D43BD2.7FC365F0>
Content-Transfer-Encoding: base64
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--_007_SYXPR01MB0463964C2DD1263171DC8222C50E0SYXPR01MB0463ausp_
Content-Type: image/png; name="image002.png"
Content-Description: image002.png
Content-Disposition: inline; filename="image002.png"; size=1316;
	creation-date="Fri, 24 Aug 2018 07:47:20 GMT";
	modification-date="Fri, 24 Aug 2018 07:47:20 GMT"
Content-ID: <image002.png@01D43BD2.7FC365F0>
Content-Transfer-Encoding: base64
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--_007_SYXPR01MB0463964C2DD1263171DC8222C50E0SYXPR01MB0463ausp_
Content-Type: image/png; name="image003.png"
Content-Description: image003.png
Content-Disposition: inline; filename="image003.png"; size=992;
	creation-date="Fri, 24 Aug 2018 07:47:20 GMT";
	modification-date="Fri, 24 Aug 2018 07:47:20 GMT"
Content-ID: <image003.png@01D43BD2.7FC365F0>
Content-Transfer-Encoding: base64
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--_007_SYXPR01MB0463964C2DD1263171DC8222C50E0SYXPR01MB0463ausp_
Content-Type: image/png; name="image004.png"
Content-Description: image004.png
Content-Disposition: inline; filename="image004.png"; size=1282;
	creation-date="Fri, 24 Aug 2018 07:47:20 GMT";
	modification-date="Fri, 24 Aug 2018 07:47:20 GMT"
Content-ID: <image004.png@01D43BD2.7FC365F0>
Content-Transfer-Encoding: base64
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--_007_SYXPR01MB0463964C2DD1263171DC8222C50E0SYXPR01MB0463ausp_--
